BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $54.59: Consecutive earnings misses (2); Earnings in 4 days (event risk).
BioMarin Pharmaceutical is a rare disease biotech with eight commercial therapies and $3.2B in 2025 revenues; VOXZOGO (vosoritide, achondroplasia) is the largest product at $926.9M, followed by VIMIZIM ($792.1M) and NAGLAZYME ($485.4M). A pending all-cash acquisition of Amicus... Read more
Sell if holding. Multiple concerning factors at $54.59: Consecutive earnings misses (2); Earnings in 4 days (event risk). Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 6.0/10, moderate confidence.
Passes 5/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductVOXZOGO10-K Item 1: 'we achieved $3.2 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $54.59: Consecutive earnings misses (2); Earnings in 4 days (event risk). Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $51.78. Score 6.0/10, moderate confidence.
Take-profit target: $81.15 (+49.4% upside). Prior stop was $51.78. Stop-loss: $51.78.
Earnings in 4 days (event risk); Consecutive earnings misses (2); Below 200-day MA.
BioMarin Pharmaceutical Inc. trades at a P/E of 30.1 (forward 8.0). TrendMatrix value score: 7.8/10. Verdict: Sell.
31 analysts cover BMRN with a consensus score of 4.1/5. Average price target: $90.
What does BioMarin Pharmaceutical Inc. do?BioMarin Pharmaceutical is a rare disease biotech with eight commercial therapies and $3.2B in 2025 revenues; VOXZOGO...
BioMarin Pharmaceutical is a rare disease biotech with eight commercial therapies and $3.2B in 2025 revenues; VOXZOGO (vosoritide, achondroplasia) is the largest product at $926.9M, followed by VIMIZIM ($792.1M) and NAGLAZYME ($485.4M). A pending all-cash acquisition of Amicus Therapeutics for approximately $4.8B was announced in December 2025, adding two Fabry/Pompe disease therapies.